Albingia Sale: Eurazeo Enters Exclusive Talks with Fiblac Consortium

Eurazeo, a notable private equity firm, has entered into exclusive discussions with a consortium led by La Financière de Blacailloux (Fiblac) to divest its 70% stake in Albingia, a prominent player in the French commercial insurance market. The consortium includes Fiblac, Krefeld (the family office of the Hermès families), and Fairfax Financial Holdings. The anticipated transaction aims to provide Eurazeo with approximately 289 million euros in sale revenue, demonstrating a 2.2x cash-on-cash return, inclusive of dividends. Approvals from relevant authorities are pending, and the deal is expected to be concluded by spring 2025. Albingia, currently the only independent entity in its market domain, showcases robust financial health with a solvency ratio significantly exceeding the Solvency II Directive. Eurazeo's strategy involves supporting industry-leading companies while ensuring significant returns for investors, a mission they have fulfilled through their collaboration with Albingia.